Roche and Trimeris broaden scope of HIV Partnership

22-Jun-2001

Three year joint research agreement to identify and commercialize additional HIV Fusion Inhibitor peptides

Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two companies which is focused on the development and commercialization of two investigational HIV fusion inhibitors, T-20 and T-1249. T-20 is currently in phase III clinical trials, and T-1249 is in phase I/II clinical trials.

Under the terms of the three-year agreement, which is renewable thereafter on an annual basis, Roche and Trimeris will equally fund worldwide research, development and commercialization costs, as well as share equally in profits from worldwide sales of new HIV fusion inhibitor peptides discovered after July 1, 1999. Fusion inhibitors represent a new class of HIV treatment that blocks the virus before it enters a host cell. By focusing on expanding the class beyond T-20 and T-1249, the next generation of fusion inhibitors has the potential to increase future treatment options for people living with HIV disease.

“Increasing numbers of people have HIV virus which has developed resistance to the classes of anti-HIV drugs currently available " said David Reddy, Franchise Leader - Virology, Roche. "New generations of drugs are urgently needed to address this growing need. Together, Roche and Trimeris will continue advancing this novel fusion inhibitor class.”

“Together with our partners, we intend to utilize multiple approaches to continue to improve and expand the fusion inhibitor class.” said Dani P. Bolognesi, co-founder and CEO, of Trimeris.

https://www.chemeurope.com/en/news/3618/roche-and-trimeris-broaden-scope-of-hiv-partnership.html